RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein

Autor: Peiman Liu, Jacqueline T. Hecht, Karen L. Posey, Huiqiu R. Wang, Alka C. Veerisetty, Joseph L. Alcorn
Rok vydání: 2010
Předmět:
musculoskeletal diseases
Cellular pathology
animal structures
lcsh:Medicine
Osteochondrodysplasias
Chondrocyte
Multiple epiphyseal dysplasia
Rheumatology/Cartilage Biology and Osteoarthritis
Small hairpin RNA
Pseudoachondroplasia
Mice
fluids and secretions
Chondrocytes
medicine
Extracellular
Animals
Matrilin Proteins
RNA
Messenger

RNA
Small Interfering

lcsh:Science
Glycoproteins
Cartilage oligomeric matrix protein
Extracellular Matrix Proteins
Multidisciplinary
biology
Cartilage
Genetics and Genomics/Gene Therapy
lcsh:R
Cell Biology/Extra-Cellular Matrix
medicine.disease
musculoskeletal system
Molecular biology
carbohydrates (lipids)
Genetics and Genomics/Gene Function
medicine.anatomical_structure
Genetics and Genomics/Disease Models
biology.protein
lcsh:Q
Mutant Proteins
RNA Interference
Rheumatology/Connective Tissue Disease
Research Article
Zdroj: PLoS ONE
PLoS ONE, Vol 5, Iss 4, p e10302 (2010)
ISSN: 1932-6203
Popis: Mutations in cartilage oligomeric matrix protein (COMP), a large extracellular glycoprotein expressed in musculoskeletal tissues, cause two skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia. These mutations lead to massive intracellular retention of COMP, chondrocyte death and loss of growth plate chondrocytes that are necessary for linear growth. In contrast, COMP null mice have only minor growth plate abnormalities, normal growth and longevity. This suggests that reducing mutant and wild-type COMP expression in chondrocytes may prevent the toxic cellular phenotype causing the skeletal dysplasias. We tested this hypothesis using RNA interference to reduce steady state levels of COMP mRNA. A panel of shRNAs directed against COMP was tested. One shRNA (3B) reduced endogenous and recombinant COMP mRNA dramatically, regardless of expression levels. The activity of the shRNA against COMP mRNA was maintained for up to 10 weeks. We also demonstrate that this treatment reduced ER stress. Moreover, we show that reducing steady state levels of COMP mRNA alleviates intracellular retention of other extracellular matrix proteins associated with the pseudoachondroplasia cellular pathology. These findings are a proof of principle and the foundation for the development of a therapeutic intervention based on reduction of COMP expression.
Databáze: OpenAIRE